Nowadays there is a strong interest in optimising human health through manipulation of non-digestible carbohydrates (NDC). NDC can be used as substrates by gut microbiota, which results in NDC degradation, production of fermentation products, such as short-chain fatty acids (SCFA), and a shift in microbiome composition and activity. It is hypothesized that SCFAs mediate parts of the beneficial effects of NDC. In mice, the influx of SCFA into the host correlated strongly with improvements of markers of the metabolic syndrome, in contrast to the concentrations of SCFA in the proximal colon. Therefore, the influx of short chain fatty acids (SCFA) into the body may be of high importance in improving metabolism. There is a need for more studies in humans to trace the life course of SCFA and their regulatory role in human metabolism. To study this inner world of bacterial products in humans, we will use a nasal-intestine catheter that can be used for delivery of components and sampling chyme in the proximal colon. Before the proposed methodology can be applied in a large intervention study, a small scale feasibility study needs to be performed that addresses colonic placement of the nasal-intestine cathether and colonic sampling of regular and NDC-enriched chyme samples. We will investigate the acute fermentation of fructo- and galacto-oligosaccharides in the proximal colon. Moreover, we will deliver 13C-labelled SCFA via a naso-intestinal catheter to quantify the fluxes of SCFA production, interconversion and uptake by the host. A small-scale, 7-day parallel feasibility trial, N=5 subjects will receive GOS/FOS supplements (mix 1:1 ratio, 15 gram/day), and N=5 other subjects will receive placebo supplements (isocaloric maltodextrin, 12 gram/day). At the last day of the supplementation period, the catheter will be placed, and afterwards participants stay maximum 5 hours in the hospital, to ensure progression of the nose-intestine catheter. After an overnight fast, subjects will visit the hospital again for measurements. Subjects will consume a NDC bolus (200 mL tap water, 5 gram fructo-oligosaccharides, 5 gram galacto-oligosaccharides, non-absorbable marker (PEG-4000). Afterwards, they are not allowed to eat for 6.5 hours. Isotopically 13C-labelled SCFAs will be delivered in the proximal colon. Blood and colonic luminal samples, breath samples, faeces and urine will be collected.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
10
15 gram/day fructo- and galacto-oligosaccharides
Wageningen University and Research
Wageningen, Netherlands
RECRUITINGConcentrations of carbohydrates
mono-, di-, tri-, oligo- and polysaccharides in the intestinal lumen
Time frame: Between 0 and 400 minutes
Relative microbiota composition and metabolites
Microbiota and metabolites inside the intestine
Time frame: Between 0 and 400 minutes
Concentrations of plasma metabolites
organic acids, amino acids, glucose, cholesterol, fatty acids and bile acids in blood
Time frame: Between 0 and 400 minutes
Catheter placement in the colon
To show placement of a naso-intestinal catheter in the proximal colon.
Time frame: After 1 week
Volume of colon sample (mL)
To check whether enough material for analysis is obtained if the catheter system takes samples in the proximal colon of participants.
Time frame: Between 0 and 400 minutes
Concentrations of SCFAs
(13C isotopic) enrichments of SCFAs inside intestinal lumen
Time frame: Between 0 and 400 minutes
Concentrations of urine metabolites
hippurate, di- en tri-methylamine, acetaldehydes, taurine, glycine, glucuronic acid conjugates, and bile acid profiles (conjugates)
Time frame: After 0 and 120 minutes
Questionnaires about (dis)comfort of study procedures
Questions about study procedures
Time frame: After 1 week
Relative microbiota composition and metabolite concentrations
Microbiota and metabolome in faeces
Time frame: After 1 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.